RESEARCH & EVIDENCE
A proteomic biomarker discovery platform for predicting clinical benefit of immunotherapy in advanced melanoma
Read More >
A proteomics-based biomarker discovery platform for predicting clinical response to immune checkpoint inhibitor therapy in non-small cell lung cancer
Read More >
21 Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients
Read More >
Proteomics of Microparticles with SILAC Quantification (PROMIS-Quan): A Novel Proteomic Method for Plasma Biomarker Quantification
Read More >
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
Read More >